Evolution of antifungals for invasive mold infections in immunocompromised hosts, then and now

References

• Nnadi NE, Carter DA, Jabra-Rizk MA. Climate change and the emergence of fungal pathogens. PLOS Pathog. 2021;17:e1009503.
   PubMed Web of Science ®Google Scholar
• Berger S, El Chazli Y, Babu AF, et al. Azole resistance in aspergillus fumigatus: a consequence of antifungal use in agriculture? Front Microbiol. 2017;8:1024. DOI:10.3389/fmicb.2017.01024
   PubMed Web of Science ®Google Scholar
• Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, et al. Sixty years of amphotericin b: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10:115–147.
   PubMed Web of Science ®Google Scholar
• Al-Mohsen I, Hughes WT. Systemic antifungal therapy: past, present and future. Ann Saudi Med. 1998;18:28–38.
   PubMed Web of Science ®Google Scholar
• Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am. 2016;30:51–83.
   PubMed Web of Science ®Google Scholar
• Kneale M, Bartholomew JS, Davies E, et al. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother. 2016;71:3599–3606.
   PubMed Web of Science ®Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(Suppl 1):1–10.
   PubMed Web of Science ®Google Scholar
• Maxfield L, Preuss CV, Bermudez R. Terbinafine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Oct 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545218/
   Google Scholar
• Vazquez JA. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis. 2008;46:1889–1901.
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142–1151.
   PubMed Web of Science ®Google Scholar
• Hüttel W. Echinocandins: structural diversity, biosynthesis, and development of antimycotics. Appl Microbiol Biotechnol. 2021;105:55–66.
   PubMed Web of Science ®Google Scholar
• Patterson TF, GR T 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–60. DOI:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Greer ND. Voriconazole: the newest triazole antifungal agent. Proc. 2003;16:241–248.
   Google Scholar
• Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol. 1976;83:367–382.
   PubMed Web of Science ®Google Scholar
• Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-β-cydodextrin (SBECD) [Internet]. J Pharmaceut sci. Available from 2010;99:3291–3301. DOI:10.1002/jps.22109
   PubMed Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209:1941–1948.
   PubMed Web of Science ®Google Scholar
• Tan I, Lomasney L, Stacy GS, et al. Spectrum of voriconazole-induced periostitis with review of the differential diagnosis. AJR Am J Roentgenol. 2019;212:157–165.
   PubMed Web of Science ®Google Scholar
• Park WB, Kim N-H, Kim K-H, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080–1087.
   PubMed Web of Science ®Google Scholar
• Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015;8:321–334.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347.
   PubMed Web of Science ®Google Scholar
• Kraljevic M, Khanna N, Medinger M, et al. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59:701–711.
   PubMed Web of Science ®Google Scholar
• Chin A, Pergam SA, Fredricks DN, et al. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob Agents Chemother. InternetAvailable from 2017;61:61. DOI: 10.1128/AAC.00569-17
   Web of Science ®Google Scholar
• Van Matre ET, Evans SL, Mueller SW, et al. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center. Ann Clin Microbiol Antimicrob. 2019;18:13.
   PubMed Web of Science ®Google Scholar
• Burks C, Darby A, Gómez Londoño L, et al. Azole-resistant Aspergillus fumigatus in the environment: identifying key reservoirs and hotspots of antifungal resistance. PLOS Pathog. 2021;17:e1009711.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Antifungal susceptibility testing: a primer for clinicians. Open Forum Infect Dis. 2021;8:ofab444. DOI:10.1093/ofid/ofab444
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Ghannoum MA, Alexander BD. Establishment and use of epidemiological cutoff values for molds and yeasts by use of the clinical and laboratory standards institute M57 standard. J Clin Microbiol. 2017;55:1262–1268.
   PubMed Web of Science ®Google Scholar
• CLSI. Epidemiological cutoff values for antifungal susceptibility testing, M59Ed3E. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Seyedmousavi S, Meletiadis J, Melchers WJG, et al. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57:796–803.
   PubMed Web of Science ®Google Scholar
• Campitelli M, Zeineddine N, Samaha G, et al. Combination antifungal therapy: a review of current data. J Clin Med Res. 2017;9:451–456.
   PubMedGoogle Scholar
• Screening for triazole-resistant Aspergillus fumigatus using agar plates [Internet]. 2021 [cited 2022 Dec 15]. Available from: https://www.cdc.gov/fungal/lab-professionals/azole-resistant-aspergillus.html.
   Google Scholar
• Pelzer BW, Seufert R, Koldehoff M, et al. Performance of the AsperGenius® PCR assay for detecting azole resistant Aspergillus fumigatus in BAL fluids from allogeneic HSCT recipients: a prospective cohort study from Essen, West Germany. Med Mycol. 2019;58:268–271.
   Web of Science ®Google Scholar
• Badali H, Wiederhold NP. Antifungal resistance testing and implications for management. Curr Fungal Infect Rep. 2019;13:274–283. 10.1007/s12281-019-00354-6
   Web of Science ®Google Scholar
• Latgé J-P, Chamilos G, Aspergillus fumigatus and Aspergillosis in 2019 [Internet]. Clinical Microbiology Reviews. 33: Available from. 2019; DOI:10.1128/cmr.00140-18
   PubMed Web of Science ®Google Scholar
• Der Linden JWM V, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49(Suppl 1):S82–89.
   PubMedGoogle Scholar
• Egli A, Fuller J, Humar A, et al. Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation. 2012;94:403–410.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. InternetAvailable from 2010;48:3251–3257. DOI:10.1128/jcm.00536-10
   PubMed Web of Science ®Google Scholar
• Hagiwara D, Watanabe A, Kamei K, et al. Epidemiological and genomic landscape of azole resistance mechanisms in aspergillus fungi. Front Microbiol. 2016;7:1382.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Jabr R, Anderson AD, et al. Successful treatment of disseminated disease due to highly resistant aspergillus calidoustus with a novel antifungal therapy. Antimicrob Agents Chemother. 2022;66:e0220621.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, DK B Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192–198.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new “gold standard. Clin Infect Dis. 2003;37:415–425.
   PubMed Web of Science ®Google Scholar
• Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am j med. 1994;97:135–144. DOI:10.1016/0002-9343(94)90023-X
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415. DOI:10.1056/NEJMoa020191
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Patterson TF, Slavin MA, et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis. 2015;60:713–720.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Boucher HW, Herbrecht R, et al. Strategy Of following voriconazole versus amphotericin b therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome [Internet]. Clinl Infect Dis. Available from 2005;41:1448–1452. DOI:10.1086/497126
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2–12. DOI:10.1086/508774
   PubMed Web of Science ®Google Scholar
• Maertens JA, II R, KA M, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769. DOI:10.1016/S0140-6736(15)01159-9
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Kuessner D, Pooley N, et al. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. Curr Med Res Opin. 2018;34:2187–2195.
   PubMed Web of Science ®Google Scholar
• Bellanger A-P, Berceanu A, Scherer E, et al. Invasive fungal disease, isavuconazole treatment failure, and death in acute myeloid leukemia patients. Emerg Infect Dis. 2019;25:1778–1779.
   PubMed Web of Science ®Google Scholar
• Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018;67:1142–1143.
   PubMed Web of Science ®Google Scholar
• Cheng MP, Orejas JL, Arbona-Haddad E, et al. Use of triazoles for the treatment of invasive aspergillosis: a three-year cohort analysis. Mycoses. 2020;63:58–64.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee D-G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397:499–509. DOI:10.1016/S0140-6736(21)00219-1
   PubMed Web of Science ®Google Scholar
• Barde F, Billaud E, Goldwirt L, et al. Low central nervous system posaconazole concentrations during cerebral phaeohyphomycosis. Antimicrob Agents Chemother. 2019;63. InternetAvailable from. DOI:10.1128/AAC.01184-19
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload Trial) [Internet]. Clinl Infect Dis. Available from 2007;44:1289–1297. DOI:10.1086/514341
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European organisation for research and treatment of cancer study. Bone Marrow Transplant. 2010;45:1227–1233.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64:1274–1281.
   PubMed Web of Science ®Google Scholar
• Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61:410–418.
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337–349. DOI:10.1016/j.jinf.2006.03.003
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–1571.
   PubMed Web of Science ®Google Scholar
• Panackal AA. Combination antifungal therapy for invasive aspergillosis revisited. Med Mycol Open Access. InternetAvailable from. 2016. 2. DOI:10.21767/2471-8521.100012
   PubMedGoogle Scholar
• Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014;28:80–94. DOI:10.1016/j.ijid.2014.07.007
   PubMed Web of Science ®Google Scholar
• Wattier RL, Dvorak CC, Hoffman JA, et al. A prospective, international cohort study of invasive mold infections in children. J Pediatric Infect Dis Soc. 2015;4:313–322.
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162:81–89. DOI:10.7326/M13-2508
   PubMed Web of Science ®Google Scholar
• II R, AE Z, GE H, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45:283–288.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194:1008–1018.
   PubMed Web of Science ®Google Scholar
• Sugar AM. Antifungal combination therapy: where we stand. Drug Resist Updat. 1998;1:89–92.
   PubMed Web of Science ®Google Scholar
• Sugar AM. Overview: antifungal combination therapy. Curr Opin Invest Drugs. 2001;2:1364–1365.
   PubMedGoogle Scholar
• Buil JB, Snelders E, Denardi LB, et al. Trends in azole resistance in aspergillus fumigatus, the Netherlands, 1994-2016. Emerg Infect Dis. 2019;25:176–178.
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Lee HAL, Rijs AJMM, et al. High-level pan-azole-resistant aspergillosis. J Clin Microbiol. 2015;53:2343–2345.
   PubMed Web of Science ®Google Scholar
• Heo ST, Tatara AM, Jiménez-Ortigosa C, et al. Changes In in vitro susceptibility patterns of aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999–2015. Clin Infect Dis. 2017;65:216–225.
   PubMed Web of Science ®Google Scholar
• Rivero-Menendez O, Soto-Debran JC, Cuenca-Estrella M, et al. In Vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies. J Fungi (Basel). 2021;7:232. DOI:10.3390/jof7030232
   PubMedGoogle Scholar
• Open-label study of APX001 for treatment of patients with invasive mold infections caused by aspergillus or rare molds - full text view - ClinicalTrials.Gov [Internet]. [cited 2023 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT04240886.
   Google Scholar
• Ghannoum M, Long L, Larkin EL, et al. Evaluation Of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. Antimicrob Agents Chemother. 2018;62. InternetAvailable from. DOI:10.1128/AAC.00244-18
   Web of Science ®Google Scholar
• Rauseo AM, Coler-Reilly A, Larson L, et al. Hope on The horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7:ofaa016.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Verweij PE, Lanuza EF, et al. 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32). Open Forum Infect Dis. 2022;9:ofac492.063.
   Google Scholar
• Kline A, Lionakis MS. Case commentary: long-term fosmanogepix use in a transplant recipient with disseminated aspergillosis caused by azole-resistant aspergillus calidoustus. Antimicrob Agents Chemother. 2022;66:e0236821.
   PubMed Web of Science ®Google Scholar
• Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19:745–751.
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl 3):27–46. DOI:10.1111/1469-0691.12465
   PubMed Web of Science ®Google Scholar
• Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90:999–1008.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704.
   PubMed Web of Science ®Google Scholar
• Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect. 2010;60:331–337.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–4450.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–319.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European confederation of medical mycology in cooperation with the international society for human and animal mycology and the American society for microbiology. Lancet Infect Dis. 2021;21:e246–257. DOI:10.1016/S1473-3099(20)30784-2
   PubMed Web of Science ®Google Scholar
• Nucci M, Jenks J, Thompson GR, et al. Do high MICs predict the outcome in invasive fusariosis? J Antimicrob Chemother. 2021;76:1063–1069.
   PubMed Web of Science ®Google Scholar
• Pérez-Nadales E, Alastruey-Izquierdo A, Linares-Sicilia MJ, et al. Invasive fusariosis in nonneutropenic patients, Spain, 2000-2015. Emerg Infect Dis. 2021;27:26–35.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less‐common, emerging, or refractory fungal infections [internet]. Clinl Infect Dis. Available from 2003;36:1122–1131. DOI:10.1086/374557
   PubMed Web of Science ®Google Scholar
• II R, RY H, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–1403.
   PubMed Web of Science ®Google Scholar
• Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation. 2003;76:1632–1637.
   PubMed Web of Science ®Google Scholar
• Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365–1366.
   PubMed Web of Science ®Google Scholar
• Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004;23:1059–1061.
   PubMed Web of Science ®Google Scholar
• Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898–4900.
   PubMed Web of Science ®Google Scholar
• Ho DY, Lee JD, Rosso F, et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227–231.
   PubMed Web of Science ®Google Scholar
• Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394–397.
   PubMed Web of Science ®Google Scholar
• Stempel JM, Hammond SP, Sutton DA, et al. Invasive fusariosis in the voriconazole era: single-center 13-year experience. Open Forum Infect Dis. 2015;2:ofv099.
   PubMed Web of Science ®Google Scholar
• Inano S, Kimura M, Iida J, et al. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review. J Infect Chemother. 2013;19:1173–1180.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81:1703–1729. DOI:10.1007/s40265-021-01611-0
   PubMed Web of Science ®Google Scholar
• Bhagavatula S, Vale L, Evans J, et al. Scedosporium prolificans osteomyelitis following penetrating injury: a case report. Med Mycol Case Rep. 2014;4:26–29.
   PubMedGoogle Scholar
• Steinbach WJ, Schell WA, Miller JL, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981–3985.
   PubMed Web of Science ®Google Scholar
• Kowacs PA, Soares Silvado CE, Monteiro de Almeida S, et al. Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors. J Clin Pathol. 2004;57:205–207.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Gibas CFC. From the clinical mycology laboratory: new species and changes in fungal taxonomy and nomenclature. J Fungi (Basel). 2018;4:138. InternetAvailable from. DOI:10.3390/jof4040138
   PubMedGoogle Scholar
• Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–1750.
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–197.
   PubMed Web of Science ®Google Scholar
• Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis. 2014;16:578–587.
   PubMed Web of Science ®Google Scholar
• Seidel D, Meißner A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019;45:1–21.
   PubMed Web of Science ®Google Scholar
• Husain S, Munoz P, Forrest G, et al. Infections due to scedosporium apiospermum and scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome [Internet]. Clinl Infect Dis. 2005;89–99. Available from. DOI:10.1086/426445
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Peter J, McGough DA, et al. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother. 1995;39:1361–1364.
   PubMed Web of Science ®Google Scholar
• Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998;42:282–288.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Ruiz-Díez B, Martínez-Suárez JV, et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 1999;43:149–151.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741–745.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Meis JFGM, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62–68.
   PubMed Web of Science ®Google Scholar
• Nomdedéu J, Brunet S, Martino R, et al. Successful treatment of pneumonia due to scedosporium apiospermum with itraconazole: case report. Clin Infect Dis. 1993;16:731–733.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Geha DJ, Marshall WF, et al. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis. 1993;16:803–805.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Winston DJ, Mukwaya G, et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. 2002;34:1648–1650.
   PubMed Web of Science ®Google Scholar
• Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001;45:2151–2153.
   PubMed Web of Science ®Google Scholar
• Jenks JD, Seidel D, Cornely OA, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope® registry. Mycoses. 2020;63:437–442.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 2000;44:470–472.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Meis JFGM, et al. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106–117.
   PubMed Web of Science ®Google Scholar
• Howden BP, Slavin MA, Schwarer AP, et al. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–113.
   PubMed Web of Science ®Google Scholar
• Whyte M, Irving H, O’Regan P, et al. DISSEMINATED SCEDOSPORIUM PROLIFICANS INFECTION and SURVIVAL of a CHILD with ACUTE LYMPHOBLASTIC LEUKEMIA [Internet]. Pediatr Infect Dis J. Available from 2005;24:375–377. DOI:10.1097/01.inf.0000157213.94392.30
   PubMed Web of Science ®Google Scholar
• Bhat SV, Paterson DL, Rinaldi MG, et al. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis. 2007;39:87–90.
   PubMed Web of Science ®Google Scholar
• Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, candida, aspergillus, fusarium, and scedosporium species. Antimicrob Agents Chemother. 2008;52:1396–1400.
   PubMed Web of Science ®Google Scholar
• Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2020;75:3582–3585.
   PubMed Web of Science ®Google Scholar
• Biswas C, Law D, Birch M, et al. In vitro activity of the novel antifungal compound F901318 against Australian scedosporium and lomentospora fungi. Med Mycol. 2018;56:1050–1054.
   PubMed Web of Science ®Google Scholar
• Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635–2642.
   PubMed Web of Science ®Google Scholar
• Kirchhoff L, Dittmer S, Buer J, et al. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020;56:106105.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Review of the novel investigational antifungal olorofim. J Fungi (Basel). 2020;6:122. InternetAvailable from. DOI:10.3390/jof6030122
   PubMedGoogle Scholar
• Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2021;10:507.
   PubMedGoogle Scholar
• Gale GR, Welch AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci. 1961;241:604–612.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19:e405–421.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:e543–552.
   PubMedGoogle Scholar
• Husain S, Silveira FP, Azie N, et al. Epidemiological features of invasive mold infections among solid organ transplant recipients: pATH Alliance®registry analysis [Internet]. Med Mycol. 2016;myw086. Available from. DOI:10.1093/mmy/myw086
   Web of Science ®Google Scholar
• Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis. 2013;15:233–242.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective Surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clinl Infect Dis. Available from 2010;50:1091–1100. DOI:10.1086/651263
   PubMed Web of Science ®Google Scholar
• Freeman Weiss Z, Leon A, Koo S. The evolving landscape of fungal diagnostics, current and emerging microbiological approaches. J Fungi (Basel) 2021;7. InternetAvailable from. DOI:10.3390/jof7020127
   PubMedGoogle Scholar
• Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French multicentre cohort study (2003-2008). Clin Microbiol Infect. 2012;18:E396–400.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order [Internet]. Antimicrob Agents Chemother. 2015;59:7735–7742. Available from. DOI:10.1128/aac.01919-15
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Sutton DA, Fothergill AW, et al. In Vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents [Internet]. Antimicrob Agents Chemother. Available from 2007;51:2587–2590. DOI: 10.1128/aac.00452-07
   PubMed Web of Science ®Google Scholar
• Lamoth F, Damonti L, Alexander BD. Role of antifungal susceptibility testing in non-aspergillus invasive mold infections. J Clin Microbiol. 2016;54:1638–1640. DOI:10.1128/JCM.00318-16
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2011;67:715–722. DOI:10.1093/jac/dkr375
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487–3496.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin b lipid complex and liposomal amphotericin b in a murine model of pulmonary mucormycosis [Internet]. Antimicrob Agents Chemother. Available from 2010;54:1298–1304. DOI:10.1128/aac.01222-09
   PubMed Web of Science ®Google Scholar
• Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70:3116–3123.
   PubMed Web of Science ®Google Scholar
• Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother. 2011;55:5018–5021.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837. DOI:10.1016/S1473-3099(16)00071-2
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–371.
   PubMed Web of Science ®Google Scholar
• Klimko NN, Khostelidi SN, Volkova AG, et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. Mycoses. 2014;57(Suppl 3):91–96. DOI:10.1111/myc.12247
   PubMedGoogle Scholar
• Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by mucorales, lomentospora prolificans and fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52:706–712.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22:811.e1–e811.e8.
   PubMed Web of Science ®Google Scholar
• Abidi MZ, Sohail MR, Cummins N, et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses. 2014;57:687–698.
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653.
   PubMed Web of Science ®Google Scholar
• Rodríguez MM, Pastor M, Javier Pastor F, et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against rhizopus microsporus in a murine disseminated infection [Internet]. Antimicrob Agents Chemother. Available from 2009;53:5022–5025. DOI:10.1128/aac.01026-09
   PubMed Web of Science ®Google Scholar
• Rodríguez MM, Pastor FJ, Sutton DA, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother. 2010;54:1665–1669.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55:4652–4658.
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Alkhazraji S, Alqarihi A, et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus. Antimicrob Agents Chemother. 2020;64. InternetAvailable from. DOI:10.1128/AAC.00178-20
   Web of Science ®Google Scholar
• Gebremariam T, Gu Y, Alkhazraji S, et al. LB1580. Efficacy assessment of MAT2203 encochleated oral formulation of amphotericin b, in the neutropenic mouse model of pulmonary mucormycosis. Open Forum Infect Dis. 2022;9(ofac492):1890. DOI:10.1093/ofid/ofac492.1890
   Google Scholar
• Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of cancer consensus criteria. Clin Infect Dis. 2008;47:674–683. DOI:10.1086/590566
   PubMed Web of Science ®Google Scholar
• Maertens JA, Thompson GR, Spec A, et al. 754. Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: interim results from a Phase 2b open-label study (NCT03583164, Study 32). Open Forum Infect Dis. 2022;9:ofac492.039.
   Google Scholar